https://www.selleckchem.com/pr....oducts/bgb-3245-brim
Finally, the current pipeline, including several novel nonbiological small molecules, such as Janus kinase (JAK) inhibitors, that are currently being evaluated in clinical trials are also presented. The availability of newer therapeutic agents has substantially changed the treatment strategy for PsA. In the future, a personalized treatment approach will probably achieve better control of disease manifestations. The availability of newer therapeutic agents has substantially changed the treatment strategy for PsA. In the fut
Gefällt mir
Kommentar
Teilen
